Steven Macina, DO
Psychiatry · Huntington Beach, CANPI 1124130471
Payments from drug & device makers
Across 1,587 payments — averaging $6992.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$4.9M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3.3M
- Sumitomo Pharma America, Inc.$547K
- E.r. Squibb & Sons, L.L.C.$475K
- Sunovion Pharmaceuticals Inc.$383K
- AbbVie$381K
- plus $1.1M from 17 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 330 | $4,908,203 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 798 | $3,254,052 |
| Sumitomo Pharma America, Inc. | 183 | $547,345 |
| E.r. Squibb & Sons, L.L.C. | 29 | $474,781 |
| Sunovion Pharmaceuticals Inc. | 84 | $383,184 |
| AbbVie | 12 | $380,928 |
| Janssen Research & Development, LLC | 36 | $243,309 |
| Biogen | 1 | $210,030 |
| Boehringer Ingelheim | 6 | $197,684 |
| Novo Nordisk AS | 43 | $154,706 |
| Amgen(2 entities) | 6 | $94,487 |
| Avanir Pharmaceuticals, Inc. | 15 | $72,139 |
| Acadia Pharmaceuticals Inc | 11 | $70,414 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $64,733 |
| Tolmar, Inc. | 3 | $35,633 |
| Neurocrine Biosciences, Inc. | 9 | $3,791 |
| Alkermes, Inc. | 3 | $363 |
| Boehringer Ingelheim International GmbH | 2 | $342 |
| Otsuka America Pharmaceutical, Inc. | 4 | $169 |
| Eisai Inc. | 1 | $120 |
| Indivior Inc. | 3 | $49 |
| Johnson & Johnson | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
How this compares
$11,096,489 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Huntington Beach
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
- Gustavo AlvaOrange$9.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.